23 Jul, 2026
Oxygen-conserving devices (OCDs), which lower pressure, control how much oxygen is delivered to the patient from the oxygen source. Oxygen conservation devices are used to treat patients with severe lung diseases, such as cystic fibrosis, diffuse interstitial lung disease, chronic obstructive pulmonary disease, or symptoms related to hypoxia, who require long-term oxygen therapy to maintain a normal lifestyle. Oxygen conservation devices can be divided into two main categories: pneumatic and electronic. Pneumatic oxygen conservation devices use high-pressure oxygen gas. In contrast to electronic oxygen conservation devices, which are battery-powered, they don't need external power like a battery. For instance, a pneumatic oxygen conservation device like the Invacare Pneumatic Oxygen Conserver features liter flow and continuous flow modes in addition to an on/off selector knob. Two AA batteries power the Evolution Electronic Oxygen Conserver from CHAD Therapeutics. In contrast to the Evolution, which has a pulse range of 14 to 40 breaths per minute, the Invacare consistently delivers volume. The primary factor driving the market for oxygen-conservation devices is the increase in people with chronic lung conditions.
Growing Adoption by Chronic Respiratory Disease Patients Drives the Market
The healthcare industry has grown significantly over the past two decades due to new technologies, unmet needs, increasing demand for better medication and treatment, and the emergence of various medical devices. Patients with chronic hypercapnic respiratory and obstructive pulmonary diseases are believed to respond best to oxygen therapy. Numerous studies have emphasized the value of oxygen therapy in treating dyspnea and relieving several conditions connected to hypercapnic chronic respiratory diseases, such as pulmonary hypertension. Despite significant advancements, doctors still find it challenging to recommend oxygen to patients for at-home therapy and to write prescriptions for it. The use of various oxygen-saving devices and techniques, either alone or in combination, is increasing due to recent market introductions. Patients who require oxygen therapy frequently use oxygen conservation devices while out and away from homecare settings.
R&D Lead to Improvement of Oxygen Conserving Devices Creates Opportunities
The development of advanced oxygen-conserving devices is anticipated to rely on research activities heavily. To maximize the number of oxygen patients inhale, market participants in oxygen-conserving devices focus on improving their design. Pneumatic, electronic, and disposable devices for oxygen conservation are currently on the market. Compared to disposable oxygen conservers, the adoption of pneumatic and electronic devices is anticipated to remain higher. While stakeholders continue to focus on improving their products' design, a flood of portable oxygen-saving devices is on the market. Responsive Respiratory Inc. created a disposable, lightweight oxygen-conserving device for challenging patients to saturate. Due to the new device's built-in humidification effect, additional humidification is unnecessary. It is anticipated that pneumatic and electronic oxygen-conserving devices will make up about 72% of the market for oxygen-conserving devices.
North America is the most significant contributor to the global oxygen conservation devices market and is anticipated to grow at a CAGR of 11.6% during the forecast period. The Institute for Health Metrics and Evaluation estimates that chronic respiratory diseases caused 6.7% of all deaths reported in the United States due to the rapidly increasing prevalence of chronic obstructive pulmonary disease and asthma. In the United States, the death rates from chronic respiratory diseases increased by 30% depending on the type of disease, the sex, and the county. Additionally, ongoing clinical trials for O2 therapy and significant investments in research and development are likely to support the growth of the North American market for oxygen conservation devices. The rising prevalence of chronic respiratory diseases will increase the market share for oxygen conservation devices in North America.
LAMEA is expected to grow at a CAGR of 12.4% during the forecast period. The rising rate of medical tourism from countries like Dubai, Abu Dhabi, and Qatar to India and other nearby countries in search of better and more affordable medical facilities is likely further to restrain the growth of the Middle East market. Africa is predicted to make a minor contribution to the regional market for oxygen conservation devices because of the low public awareness of the harmful effects of smoking. The number of cigarette smokers in the area is expected to rise over the next few years, and notable players' businesses are expected to grow as a result. This is primarily due to inadequate healthcare infrastructure, a lack of oxygen conservation devices in the region, and a lack of public awareness of respiratory diseases like asthma and COPD.
sales@straitsresearch.com